

Correction: *Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE*

Casey KA, Guo X, Smith MA, *et al.* Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. *Lupus Science, Medicine* 2018;5:e000286. doi: 10.1136/lupus-2018-000286

This article has been corrected since it first published. This is to inform that co-author Wendy I White's affiliation was addressed incorrectly. Her correct affiliation is: Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.

Below is the updated information on the authors' affiliation.

Kerry A Casey,¹ Xiang Guo,² Michael A Smith,¹ Shiliang Wang,² Dominic Sinibaldi,³ Miguel A Sanjuan,¹ Liangwei Wang,⁴ Gabor G Illei,⁵ Wendy I White²

¹Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA

²Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA

³Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA

⁴Biostatistics, MedImmune LLC, Gaithersburg, Maryland, USA

⁵Clinical Development, MedImmune LLC, Gaithersburg, Maryland, USA



OPEN ACCESS

Open access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Lupus Sci Med 2018;5:e000286corr1. doi:10.1136/lupus-2018-000286corr1

